Skip to main content

Featured

Iran–U.S. Negotiations & Shipping Disruptions: What It Means for Your Wallet

  🔴 Breaking — This Morning President Trump posted on social media Saturday that a peace deal with Iran is "largely negotiated" and will be announced shortly. The Washington Post reports (May 25, 2026) that the U.S. and Iran are actively working toward a framework deal that would extend the ceasefire and reopen the Strait of Hormuz. Oil prices have already reacted — Brent crude fell more than 5% to around $98 a barrel on the news. After nearly three months of conflict, spiralling energy prices, and stalled talks, there is cautious optimism today that a diplomatic breakthrough between the United States and Iran could be imminent. But what exactly is being negotiated — and what does it actually mean for Canadians and consumers at the gas pump, the grocery store, and beyond? Here is everything you need to know, updated with today's latest developments. $4.51 U.S. avg. gas price/gallon — up 51% since the war began -5.2% Brent crude drop today on deal optimism (to ~$98/barre...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment